Skip to Content
The New York City–based pharmaceutical company delivered strong financial results in 2021, with total revenue growing 9% year over year to $46.4 billion. Bristol-Myers Squibb enjoyed strong sales for drugs like Revlimid and Opdivo, used in the treatment of certain cancers; and Eliquis, an anticoagulant. Its product-development pipeline also looks healthy: In 2021, the company obtained more than 20 regulatory approvals for new medicines. 
Lists ranking Bristol-Myers Squibb
Global 500 - 2022Aggregate sales hit $37.8 trillion last year—an in...READ MOREview in list
Fortune 500 - 2022This year’s Fortune 500 marks the 68th running of ...READ MOREview in list
Fortune Modern Board 25 - 2022Fortune collaborated with the Diligent Institute t...READ MOREview in list
World’s Most Admired Companies - 2022Just as it dominates our economy, Big Tech now dom...READ MOREview in list